Cargando…

Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer

Molecularly targeted therapy has enabled outstanding advances in cancer treatment. Whereas various anti‐human epidermal growth factor receptor 2 (HER2) drugs have been developed, trastuzumab is still the only anti‐HER2 drug presently available for gastric cancer. In this study, we propose novel trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshioka, Takahiro, Shien, Kazuhiko, Namba, Kei, Torigoe, Hidejiro, Sato, Hiroki, Tomida, Shuta, Yamamoto, Hiromasa, Asano, Hiroaki, Soh, Junichi, Tsukuda, Kazunori, Nagasaka, Takeshi, Fujiwara, Toshiyoshi, Toyooka, Shinichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891184/ https://www.ncbi.nlm.nih.gov/pubmed/29465762 http://dx.doi.org/10.1111/cas.13546

Ejemplares similares

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells
por: Yoshioka, Takahiro, et al.
Publicado: (2019)

Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations
por: Ogoshi, Yusuke, et al.
Publicado: (2019)

Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway
por: Ohtsuka, Tomoaki, et al.
Publicado: (2016)

Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma
por: Namba, Kei, et al.
Publicado: (2019)

Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features
por: Sato, Hiroki, et al.
Publicado: (2017)

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
por: Sato, Hiroki, et al.
Publicado: (2018)

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations
por: Suzawa, Ken, et al.
Publicado: (2015)

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer
por: Takeda, Tatsuaki, et al.
Publicado: (2017)

YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers
por: Takeda, Tatsuaki, et al.
Publicado: (2020)

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer
por: Sato, Hiroki, et al.
Publicado: (2018)

Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis
por: Takahashi, Yuta, et al.
Publicado: (2018)

Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas
por: Yamamoto, Hiromasa, et al.
Publicado: (2013)

DV200 Index for Assessing RNA Integrity in Next-Generation Sequencing
por: Matsubara, Takehiro, et al.
Publicado: (2020)

Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib
por: Hashida, Shinsuke, et al.
Publicado: (2015)

Anti-Cancer Effects of REIC/Dkk-3-encoding Adenoviral Vector for the Treatment of Non-small Cell Lung Cancer
por: Shien, Kazuhiko, et al.
Publicado: (2014)

One-step nucleic acid amplification for intraoperative diagnosis of lymph node metastasis in lung cancer patients: a single-center prospective study
por: Namba, Kei, et al.
Publicado: (2022)

The proliferative effects of asbestos-exposed peripheral blood mononuclear cells on mesothelial cells
por: MAKI, YUHO, et al.
Publicado: (2016)

DNA methylation status of REIC/Dkk-3 gene in human malignancies
por: Hayashi, Tatsuro, et al.
Publicado: (2012)

ASO Author Reflections: Prognostic Impact of the Primary Tumor Resection for Lung Cancer Patients Diagnosed with Pleural Dissemination in the Perioperative Period—Importance of Biomarker-Based Treatment Decision Making
por: Shien, Kazuhiko, et al.
Publicado: (2023)

The Potential of panHER Inhibition in Cancer
por: Wang, Xiaochun, et al.
Publicado: (2015)

Identification of genetic loci associated with renal dysfunction after lung transplantation using an ethnic-specific single-nucleotide polymorphism array
por: Tomioka, Yasuaki, et al.
Publicado: (2023)

Author Correction: Identification of genetic loci associated with renal dysfunction after lung transplantation using an ethnic-specific single-nucleotide polymorphism array
por: Tomioka, Yasuaki, et al.
Publicado: (2023)

YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
por: Fujihara, Miwa, et al.
Publicado: (2021)

Drug repositioning of tranilast to sensitize a cancer therapy by targeting cancer‐associated fibroblast
por: Ochi, Kosuke, et al.
Publicado: (2022)

TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells
por: Otani, Hiroki, et al.
Publicado: (2015)

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study
por: Koga, Takamasa, et al.
Publicado: (2021)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy
por: Li, Ziteng, et al.
Publicado: (2020)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells
por: Ikeda, Hirokuni, et al.
Publicado: (2010)

A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis
por: Leung, Kin-Mei, et al.
Publicado: (2015)

Anti-HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma
por: Asano, Teizo, et al.
Publicado: (2021)

Induction Chemoradiotherapy Followed by Surgical Resection for Clinical T3 or T4 Locally Advanced Non–Small Cell Lung Cancer
por: Shien, Kazuhiko, et al.
Publicado: (2012)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
por: Reddy, Tejaswini P., et al.
Publicado: (2020)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pthttmqfp3omrvptauninqr405